These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22541956)

  • 1. Abatacept therapy and safety management.
    Pham T; Bachelez H; Berthelot JM; Blacher J; Claudepierre P; Constantin A; Fautrel B; Gaujoux-Viala C; Goëb V; Gossec L; Goupille P; Guillaume-Czitrom S; Hachulla E; Lequerré T; Marolleau JP; Martinez V; Masson C; Mouthon L; Puéchal X; Richette P; Saraux A; Schaeverbeke T; Soubrier M; Viguier M; Vittecoq O; Wendling D; Mariette X; Sibilia J
    Joint Bone Spine; 2012 Mar; 79 Suppl 1():3-84. PubMed ID: 22541956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha antagonist therapy and safety monitoring.
    Pham T; Bachelez H; Berthelot JM; Blacher J; Bouhnik Y; Claudepierre P; Constantin A; Fautrel B; Gaudin P; Goëb V; Gossec L; Goupille P; Guillaume-Czitrom S; Hachulla E; Huet I; Jullien D; Launay O; Lemann M; Maillefert JF; Marolleau JP; Martinez V; Masson C; Morel J; Mouthon L; Pol S; Puéchal X; Richette P; Saraux A; Schaeverbeke T; Soubrier M; Sudre A; Tran TA; Viguier M; Vittecoq O; Wendling D; Mariette X; Sibilia J
    Joint Bone Spine; 2011 May; 78 Suppl 1():15-185. PubMed ID: 21703545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab: therapy and safety management.
    Pham T; Claudepierre P; Constantin A; de Bandt M; Fautrel B; Gossec L; Gottenberg JE; Goupille P; Guillaume S; Hachulla E; Masson C; Morel J; Puéchal X; Saraux A; Schaeverbeke T; Wendling D; Bruckert E; Pol S; Mariette X; Sibilia J;
    Joint Bone Spine; 2010 Jun; 77 Suppl 1():S3-100. PubMed ID: 20610315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept therapy and safety management.
    Pham T; Claudepierre P; Constantin A; Fautrel B; Gossec L; Gottenberg JE; Goupille P; Hachulla E; Masson C; Morel J; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Sibilia J
    Joint Bone Spine; 2009 May; 76 Suppl 1():S3-S55. PubMed ID: 19560051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of abatacept in rheumatoid arthritis.
    von Kempis J; Dudler J; Hasler P; Kyburz D; Tyndall A; Zufferey P; Villiger PM
    Swiss Med Wkly; 2012; 142():w13581. PubMed ID: 22581564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
    Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Emery P; Keystone EC; Schiff MH; van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii2-15. PubMed ID: 17038465
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR).
    Pham T; Claudepierre P; Deprez X; Fautrel B; Goupille P; Hilliquin P; Masson C; Morel J; Puéchal X; Saraux A; Schaeverbeke T; Mariette X; Sibilia J;
    Joint Bone Spine; 2005 Jun; 72 Suppl 1():S1-58. PubMed ID: 15978467
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.
    Cortejoso-Fernández L; Romero-Jiménez MR; Pernía-López MS; Montoro-Álvarez M; Sanjurjo-Sáez M
    J Pharm Pharm Sci; 2012; 15(1):46-51. PubMed ID: 22365087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept use in rheumatoid arthritis: evidence review and recommendations.
    Martín Mola E; Balsa A; Martínez Taboada V; Sanmartí R; Marenco JL; Navarro Sarabia F; Gómez-Reino J; Alvaro-Gracia JM; Román Ivorra JA; Lojo L; Plasencia C; Carmona L;
    Reumatol Clin; 2013; 9(1):5-17. PubMed ID: 22766432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept.
    Vital EM; Emery P
    Drugs Today (Barc); 2006 Feb; 42(2):87-93. PubMed ID: 16541185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practice guidelines for the use of subcutaneous abatacept.
    Mola EM; Balsa A; Martínez Taboada V; Marenco JL; Navarro Sarabia F; Gómez-Reino J; Alvaro-Gracia JM; Román Ivorra JA; Lojo L; Plasencia C; Carmona L
    Reumatol Clin; 2014; 10(4):218-26. PubMed ID: 24387951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulation blockade in rheumatic diseases: where we are?
    Goëb V; Buch MH; Vital EM; Emery P
    Curr Opin Rheumatol; 2009 May; 21(3):244-50. PubMed ID: 19342956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.
    Furst DE; Keystone EC; So AK; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Rubbert-Roth A; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop KL
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii2-34. PubMed ID: 23532441
    [No Abstract]   [Full Text] [Related]  

  • 20. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i2-45. PubMed ID: 22460137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.